No Picture
News

Katana Pharmaceuticals Awarded up to $1.05 Million Innovative Challenge Grant from March of Dimes to Support the Development of a Novel Non-Opioid Treatment for Neonatal Abstinence Syndrome

SAN FRANCISCO, June 3, 2020 /PRNewswire/ — Katana Pharmaceuticals Inc. (Katana), a San Francisco-based startup biotech company developing novel treatments for neonatal patient populations and rare pediatric disorders, today announced the receipt… […]

No Picture
News

n-Lorem Foundation receives additional support for providing “n of 1” experimental antisense medicines to treat patients with ultra-rare diseases

CARLSBAD, Calif., March 12, 2020 /PRNewswire/ –?The n-Lorem Foundation announced today it has received an initial pledge of $500,000 from Mark Lampert in support of the n-Lorem Foundation’s efforts to provide advanced, experimental RNA-targeted med… […]

No Picture
News

Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata’s Bacteriophage Development Programs

MARINA DEL REY, Calif.?and BRISBANE, Calif., Jan. 28, 2020 /PRNewswire/ –?Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infec… […]

No Picture
News

Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents

Exceeds 2019 goal of $40-$50 million in cumulative contracts with pharmaceutical companies and extends leadership in ctDNA MRD

SAN CARLOS, Calif., Jan. 6, 2020 /PRNewswire/ –?Natera, Inc.?(NASDAQ: NTRA), a global leader in cell-free DNA testing, tod… […]